Day One Biopharmaceuticals Inc (NASDAQ: DAWN) is -2.05% lower on its value in year-to-date trading and has touched a low of $9.67 and a high of $18.07 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DAWN stock was last observed hovering at around $13.88 in the last trading session, with the day’s gains setting it 0.42%.
Currently trading at $14.30, the stock is 2.06% and 2.97% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.81 million and changing 3.03% at the moment leaves the stock -1.92% off its SMA200. DAWN registered 34.52% gain for a year compared to 6-month gain of 3.25%. The firm has a 50-day simple moving average (SMA 50) of $13.8874 and a 200-day simple moving average (SMA200) of $14.57965.
The stock witnessed a 1.20% loss in the last 1 month and extending the period to 3 months gives it a -10.68%, and is 5.30% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.66% over the week and 4.50% over the month.
Day One Biopharmaceuticals Inc (DAWN) has around 155 employees, a market worth around $1.25B and $8.19M in sales. Profit margin for the company is -2044.43%. Distance from 52-week low is 47.88% and -20.86% from its 52-week high. The company has generated returns on investments over the last 12 months (-54.60%).
with sales reaching $22.23M over the same period.The EPS is expected to grow by 17.62% this year.
Day One Biopharmaceuticals Inc (DAWN) Top Institutional Holders
232.0 institutions hold shares in Day One Biopharmaceuticals Inc (DAWN), with institutional investors hold 108.37% of the company’s shares. The shares outstanding are 87.23M, and float is at 59.32M with Short Float at 26.41%. Institutions hold 87.13% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 7.87 million shares valued at $108.47 million. The investor’s holdings represent 9.0814% of the DAWN Shares outstanding. As of 2024-06-30, the second largest holder is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with 6.43 million shares valued at $88.61 million to account for 7.4184 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 4.62 million shares representing 5.3338% and valued at over $63.71 million, while BLACKROCK INC. holds 5.2301 of the shares totaling 4.53 million with a market value of $62.47 million.
Day One Biopharmaceuticals Inc (DAWN) Insider Activity
The most recent transaction is an insider sale by Blackman Samuel C., the company’s HEAD OF R&D. SEC filings show that Blackman Samuel C. sold 30,000 shares of the company’s common stock on Sep 10 ’24 at a price of $14.22 per share for a total of $0.43 million. Following the sale, the insider now owns 1.1 million shares.
Day One Biopharmaceuticals Inc disclosed in a document filed with the SEC on Aug 16 ’24 that Dubow Adam (GENERAL COUNSEL) sold a total of 3,202 shares of the company’s common stock. The trade occurred on Aug 16 ’24 and was made at $14.00 per share for $44825.0. Following the transaction, the insider now directly holds 26928.0 shares of the DAWN stock.
Still, SEC filings show that on Aug 16 ’24, York Charles N II (COO, CFO AND SECRETARY) disposed off 2,633 shares at an average price of $14.00 for $36860.0. The insider now directly holds 232,485 shares of Day One Biopharmaceuticals Inc (DAWN).
